A provider briefing on Buspar (Buspirone) availability in 2026: shortage timeline, prescribing implications, cost/access landscape, and tools to help your patients.
Buspirone has been a reliable workhorse in anxiety management for decades — a non-benzodiazepine anxiolytic with a favorable safety profile, no controlled substance designation, and proven efficacy for generalized anxiety disorder (GAD). But supply disruptions in recent years have created headaches for prescribers and patients alike.
This briefing covers the current availability picture, what the shortage history means for prescribing decisions in 2026, and tools that can help your patients access their medication.
In 2019, Mylan discontinued production of certain Buspirone strengths, triggering a cascading supply disruption. The FDA added Buspirone to its drug shortage list as remaining manufacturers — Teva, Aurobindo, Par Pharmaceutical, and others — struggled to absorb the increased demand.
The timing was particularly challenging: anxiety disorder diagnoses were already trending upward, and Buspirone prescriptions had been increasing as prescribers moved away from long-term benzodiazepine use in favor of safer alternatives.
The COVID-19 pandemic exacerbated the situation. Anxiety and depression rates spiked, driving further increases in Buspirone prescriptions. Supply chain disruptions affecting raw ingredient sourcing and manufacturing capacity compounded existing production shortfalls.
Generic manufacturers expanded production capacity, and new suppliers entered the market. By mid-2023, most Buspirone strengths were consistently available at major distributors, though intermittent spot shortages continued at the pharmacy level.
As of early 2026, Buspirone is not listed on the FDA's drug shortage database. Multiple manufacturers are producing all five oral tablet strengths (5 mg, 7.5 mg, 10 mg, 15 mg, and 30 mg). Supply is generally stable, though localized inventory gaps still occur — particularly for 15 mg and 30 mg tablets at chain pharmacies.
Despite the supply history, Buspirone's clinical profile makes it an excellent option for GAD management:
For detailed interaction information, see our reference: Buspar Drug Interactions: What to Avoid.
The supply situation is favorable:
Buspirone is one of the most affordable psychiatric medications available:
Cost is rarely a barrier with Buspirone. For patients who do struggle financially, Rx Outreach and state pharmaceutical assistance programs can help. NeedyMeds (needymeds.org) maintains a current directory of assistance options.
Medfinder offers real-time pharmacy stock checking that providers can use to help patients locate Buspirone — or any medication — in stock near them. This is particularly useful when patients report difficulty filling prescriptions.
When a specific strength is unavailable, consider prescribing an equivalent dose using different tablet strengths. For example:
Most pharmacies can accommodate these substitutions without a new prescription if the total daily dose remains the same.
Because Buspirone is not a controlled substance, it can be prescribed via telehealth in all states without the restrictions that apply to scheduled medications. This expands access for patients in underserved areas or those with limited mobility.
Buspirone's position in the anxiety treatment armamentarium is secure. As prescribers continue moving toward non-benzodiazepine options for long-term GAD management, demand is likely to remain strong. The current multi-manufacturer supply base should support this demand, but staying aware of local availability patterns remains prudent.
For patient-facing information you can share, see our guides on finding Buspar in stock and saving money on Buspar.
The Buspirone shortage of 2019-2020 was a significant supply disruption that affected patient care. In 2026, the picture is much improved. Buspirone is broadly available, deeply affordable, and remains a clinically sound choice for GAD and SSRI augmentation.
When patients encounter localized stock issues, Medfinder can help them find the medication quickly. Maintaining prescribing flexibility with regard to tablet strengths and pharmacy options ensures your patients stay on their treatment plans without interruption.
For a comprehensive patient reference, see What Is Buspar? Uses, Dosage, and What You Need to Know. For clinical guidance on helping patients manage costs, see our provider's guide to helping patients save on Buspar.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
